BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder.

OBJECTIVE Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity and has been implicated in the affective disorders; studies have demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. The objective of our study was to analyze BDNF in lithium-responsive patients with bipolar disorder (BD) to further understand the role of BDNF in the pathophysiology of BD. METHODS Using enzyme-linked immunosorbent assay, we measured transformed B lymphocytes for BDNF protein. RESULTS BDNF levels were 36% lower in lymphoblasts from patients with BD (n = 12), compared with matched control participants (n = 13), and 55% lower when compared with their unaffected relatives (n = 14). Lithium significantly decreased BDNF levels in patients with BD and healthy control participants, although BDNF levels remained lower (33%) in the BD group posttreatment. CONCLUSION Decreased BDNF may constitute part of the pathophysiologic process of BD in a lithium-responsive subgroup of individuals with this disease. A compensatory mechanism protecting the genetically predisposed unaffected relatives from phenotypic expression of BD is suggested.

[1]  Chien-Te Lee,et al.  Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. , 2008, Journal of psychiatric research.

[2]  R. Post.  Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. , 2007, Journal of psychiatric research.

[3]  Frank Seifert,et al.  Correlation Between Serum Brain-Derived Neurotrophic Factor Level and An In Vivo Marker of Cortical Integrity , 2007, Biological Psychiatry.

[4]  M. Tsuang,et al.  Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder , 2007, Psychiatric genetics.

[5]  M. Dietrich,et al.  Decreased Plasma Brain Derived Neurotrophic Factor Levels in Unmedicated Bipolar Patients During Manic Episode , 2007, Biological Psychiatry.

[6]  S. Kennedy,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. , 2006, Bipolar disorders.

[7]  W. Drevets,et al.  Toward Constructing an Endophenotype Strategy for Bipolar Disorders , 2006, Biological Psychiatry.

[8]  B. Frey,et al.  Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes , 2006, Neuroscience Letters.

[9]  M. Alda,et al.  Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[10]  M. Alda,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. , 2005, Bipolar disorders.

[11]  F. Taneli,et al.  Effect of treatment on serum brain–derived neurotrophic factor levels in depressed patients , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[12]  F. Taneli,et al.  The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[13]  M. Alda.  The phenotypic spectra of bipolar disorder , 2004, European Neuropsychopharmacology.

[14]  M. Schwald,et al.  The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder. , 2004, Journal of affective disorders.

[15]  H. Manji,et al.  The Role of the Extracellular Signal-Regulated Kinase Signaling Pathway in Mood Modulation , 2003, The Journal of Neuroscience.

[16]  M. Schwald,et al.  Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets , 2002, Neuroscience Letters.

[17]  G. MacQueen,et al.  Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication , 2001, Biological Psychiatry.

[18]  M. Alda,et al.  Is lithium response related to Gsα levels in transformed lymphoblasts from subjects with bipolar disorder , 2001 .

[19]  M. Alda,et al.  Evidence for a role of phospholipase C-γ1 in the pathogenesis of bipolar disorder , 1998, Molecular Psychiatry.

[20]  D. Chuang,et al.  Lithium Increases Transcription Factor Binding to AP‐1 and Cyclic AMP‐Responsive Element in Cultured Neurons and Rat Brain , 1997, Journal of neurochemistry.

[21]  L. Young,et al.  Mood stabilizers have differential effects on endogenous ADP ribosylation in C6 glioma cells. , 1996, European journal of pharmacology.

[22]  M. Alda,et al.  Lithium response and genetics of affective disorders. , 1994, Journal of affective disorders.

[23]  H. Manji,et al.  Long‐term action of lithium: A role for transcriptional and posttranscriptional factors regulated by protein kinase C , 1994, Synapse.

[24]  T. Inubushi,et al.  Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: Relationship to erythrocyte and serum concentrations , 1993, Biological Psychiatry.

[25]  J. Endicott,et al.  A diagnostic interview: the schedule for affective disorders and schizophrenia. , 1978, Archives of general psychiatry.

[26]  E. Robins,et al.  Research diagnostic criteria: rationale and reliability. , 1978, Archives of general psychiatry.

[27]  C. Martini,et al.  Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. , 2008, Journal of affective disorders.

[28]  L. Hirsch.  Competing interests: none declared. , 2006 .

[29]  J. Kane,et al.  Extending indications for long-term pharmacotherapy: opportunities and challenges. , 2002, The American journal of psychiatry.

[30]  Dc Washington.  Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .